T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

引言恩美曲妥珠单抗（T-DM1）是全球首个获批上市的乳腺癌抗体偶联药物（ADC）。2018 年，发表于 New England Journal of Medicine 的 Ⅲ 期开放标签试验 KATHERINE ...

Impact of combined resection of pancreas on long-term survival in patients with gastric cancer. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy ...

Effectiveness of anti-epidermal growth factor receptor agents in elderly patients (age ≥ 70 years) with RAS wild-type metastatic colorectal cancer: Nationwide real-world data. This is an ASCO Meeting ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.